Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).
Arnoud J. Templeton
No relevant relationships to disclose
Lukas Stalder
No relevant relationships to disclose
Juerg Bernhard
No relevant relationships to disclose
Peter Brauchli
No relevant relationships to disclose
Silke Gillessen
Consultant or Advisory Role - Novartis
Stefanie Hayoz
No relevant relationships to disclose
Dirk Klingbiel
No relevant relationships to disclose
Klazieu Matter-Walstra
No relevant relationships to disclose
Beat J. K. Thurlimann
Stock Ownership - Novartis
Roger Von Moos
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen